West Pharmaceutical Services stock may be about 6.9% undervalued based on a narrative fair value of $352.36, compared with its last closing price of $327.95. The bullish case rests on continued growth in GLP-1 drugs, which accounted for roughly 7% of total revenues in the first quarter, and a favorable mix shift toward higher-margin high-value products supported by approximately 340 Annex 1 projects. However, the stock's current price-to-earnings ratio of 42.7 times exceeds the peer average of 38.2 times and the global Life Sciences average of 34.3 times, pointing to valuation risk if sentiment cools. Key pressure points include high-value product capacity constraints and tariff or pricing risks that could weaken the outlook.
West Pharmaceutical Services IncGLP-1 drug growth drives demand for West's components, with 7% of Q1 revenue from GLP-1 and 340 Annex 1 projects supporting high-value product mix.